Denali Therapeutics Inc. (DNLI) Shareholder Equity
- 2026-06-30: Additional Paid in CapitalUSD $3.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-1.97M; Retained Earnings (Accumulated Deficit)USD $-2.31B; Stockholders' Equity Attributable to ParentUSD $835.18M.
- 2026-03-31: Additional Paid in CapitalUSD $3.10B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-682.00K; Retained Earnings (Accumulated Deficit)USD $-2.18B; Stockholders' Equity Attributable to ParentUSD $926.10M.
- 2025-12-31: Additional Paid in CapitalUSD $3.06B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $682.00K; Retained Earnings (Accumulated Deficit)USD $-2.05B; Stockholders' Equity Attributable to ParentUSD $1.01B.
- 2025-09-30: Additional Paid in CapitalUSD $2.85B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.10M; Retained Earnings (Accumulated Deficit)USD $-1.92B; Stockholders' Equity Attributable to ParentUSD $926.20M.
Denali Therapeutics Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Preferred Stock, Value, Outstanding USD | Common Stock, Value, Outstanding USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.14B | $-1.97M | $-2.31B | $835.18M | $0.00 | $1.92M | 6 month · $45.00K | 3 month · $22.91M 6 month · $46.00M | (m) | (m) |
| 2026-03-31 | $3.10B | $-682.00K | $-2.18B | $926.10M | $0.00 | $1.91M | 3 month · $45.00K | 3 month · $23.09M | (m) | (m) |
| 2025-12-31 | $3.06B | $682.00K | $-2.05B | $1.01B | $0.00 | $1.89M | 12 month · $728.00K | 12 month · $100.25M | (m) | (m) |
| 2025-09-30 | $2.85B | $1.10M | $-1.92B | $926.20M | $0.00 | $1.79M | (m) | 3 month · $25.30M 9 month · $76.19M | (m) | (m) |
| 2025-06-30 | $2.82B | $939.00K | $-1.80B | $1.03B | $0.00 | $1.78M | (m) | 3 month · $25.53M 6 month · $50.89M | (m) | (m) |
| 2025-03-31 | $2.79B | $2.04M | $-1.67B | $1.12B | $0.00 | $1.78M | (m) | 3 month · $25.36M | (m) | (m) |
| 2024-12-31 | $2.76B | $2.02M | $-1.54B | $1.23B | $0.00 | $1.77M | 12 month · $480.00K | 12 month · $103.48M | (m) | (m) |
| 2024-09-30 | $2.74B | $5.53M | $-1.42B | $1.32B | $0.00 | $1.76M | 9 month · $480.00K | 3 month · $24.99M 9 month · $78.19M | (m) | (m) |
| 2024-06-30 | $2.70B | $-2.66M | $-1.32B | $1.39B | $0.00 | $1.76M | 6 month · $480.00K | 3 month · $25.21M 6 month · $53.20M | (m) | (m) |
| 2024-03-31 | $2.67B | $-1.30M | $-1.22B | $1.46B | $0.00 | $1.75M | 3 month · $480.00K | 3 month · $27.99M | (m) | (m) |
| 2023-12-31 | $2.14B | $643.00K | $-1.12B | $1.03B | $0.00 | $1.71M | 12 month · $1.06M | 12 month · $108.40M | $0.00 | $1.71M |
| 2023-09-30 | $2.11B | $-651.00K | $-996.74M | $1.12B | (m) | (m) | (m) | 3 month · $27.58M 9 month · $82.30M | $0.00 | $1.71M |
| 2023-06-30 | $2.08B | $-1.44M | $-897.38M | $1.19B | (m) | (m) | (m) | 3 month · $26.64M 6 month · $54.73M | $0.00 | $1.70M |
| 2023-03-31 | $2.05B | $-2.52M | $-1.08B | $966.71M | (m) | (m) | (m) | 3 month · $28.08M | $0.00 | $1.69M |
| 2022-12-31 | $2.02B | $-6.89M | $-970.99M | $1.04B | (m) | (m) | 12 month · $1.06M | 12 month · $99.85M | $0.00 | $1.69M |
| 2022-09-30 | $1.69B | $-11.85M | $-872.31M | $811.30M | (m) | (m) | (m) | 3 month · $24.58M 9 month · $74.66M | $0.00 | $1.56M |
| 2022-06-30 | $1.66B | $-12.27M | $-769.01M | $884.45M | (m) | (m) | (m) | 3 month · $23.94M 6 month · $50.08M | $0.00 | $1.56M |
| 2022-03-31 | $1.64B | $-9.25M | $-710.22M | $917.93M | (m) | (m) | (m) | 3 month · $26.14M | $0.00 | $1.55M |
| 2021-12-31 | $1.61B | $-2.50M | $-645.00M | $962.29M | (m) | (m) | (m) | 12 month · $85.25M | $0.00 | $1.55M |
| 2021-09-30 | $1.58B | $-521.00K | $-569.74M | $1.01B | (m) | (m) | (m) | 3 month · $21.00M 9 month · $63.16M | $0.00 | $1.54M |
| 2021-06-30 | $1.56B | $-368.00K | $-485.15M | $1.07B | (m) | (m) | (m) | 3 month · $21.14M 6 month · $42.16M | $0.00 | $1.54M |
| 2021-03-31 | $1.53B | $-232.00K | $-424.46M | $1.11B | (m) | (m) | (m) | 3 month · $21.03M | $0.00 | $1.54M |
| 2020-12-31 | $1.50B | $-245.00K | $-354.42M | $1.15B | (m) | (m) | (m) | 12 month · $50.35M | $0.00 | $1.53M |
| 2020-09-30 | $1.48B | $11.00K | $-599.30M | $882.55M | (m) | (m) | (m) | 3 month · $13.25M 9 month · $36.52M | $0.00 | $1.52M |
| 2020-06-30 | $1.04B | $551.00K | $-541.07M | $502.17M | (m) | (m) | (m) | 3 month · $12.48M 6 month · $23.27M | $0.00 | $1.39M |
| 2020-03-31 | $1.03B | $835.00K | $-482.31M | $545.31M | (m) | (m) | (m) | 3 month · $10.79M | $0.00 | $1.38M |
| 2019-12-31 | $818.80M | $350.00K | $-425.55M | $394.89M | (m) | (m) | (m) | 12 month · $38.38M | $0.00 | $1.29M |
| 2019-09-30 | $807.88M | $562.00K | $-371.53M | $438.20M | (m) | (m) | (m) | 3 month · $8.90M 9 month · $29.49M | $0.00 | $1.29M |
| 2019-06-30 | $798.28M | $879.00K | $-325.27M | $475.17M | (m) | (m) | (m) | 3 month · $13.71M 6 month · $20.59M | $0.00 | $1.28M |
| 2019-03-31 | $781.97M | $332.00K | $-266.93M | $516.65M | (m) | (m) | (m) | 3 month · $6.87M | $0.00 | $1.28M |
| 2018-12-31 | $774.16M | $-649.00K | $-227.94M | $546.85M | (m) | (m) | (m) | 12 month · $18.79M | $0.00 | $1.27M |
| 2018-09-30 | $766.80M | $-1.42M | $-305.47M | $461.18M | (m) | (m) | (m) | 3 month · $5.51M 9 month · $13.14M | $0.00 | $1.27M |
| 2018-06-30 | $760.61M | $-1.49M | $-270.10M | $490.27M | (m) | (m) | (m) | 3 month · $4.71M 6 month · $7.63M | $0.00 | $1.26M |
| 2018-03-31 | $754.44M | $-1.29M | $-215.38M | $539.03M | (m) | (m) | (m) | 3 month · $2.92M | (m) | $1.25M |
| 2017-12-31 | $656.66M | $-368.00K | $-191.70M | $465.80M | (m) | (m) | (m) | 12 month · $4.41M | $0.00 | $1.20M |
| 2016-12-31 | (m) | (m) | (m) | $-94.15M | (m) | (m) | (m) | 12 month · $2.95M | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | $-15.63M | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |